GDPs and AGEs: local and systemic effects in PD patients.
Ledebo
Ingrid
I
Gambro Corporate Research, Lund, Sweden. ingrid.ledebo@gambro.com
Wieslander
Anders
A
Deppisch
Reinhold
R
D002478:Cells, Cultured; D015314:Dialysis Solutions / Q000009:adverse effects* / Q000493:pharmacokinetics* / Q000494:pharmacology; D004847:Epithelial Cells / Q000187:drug effects; D005260:Female; D005500:Follow-Up Studies; D005947:Glucose / Q000378:metabolism*; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy; D008297:Male; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects* / Q000379:methods; D010537:Peritoneum / Q000166:cytology / Q000187:drug effects; D018570:Risk Assessment
D015314:Dialysis Solutions; D017127:Glycation End Products, Advanced; D005947:Glucose